Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label certolizumab pegol safety follow-on study in Crohn's disease
2007-002716-26Phase 3Completed
- Sponsor
- UCB
- Start
- Oct 2007
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of certolizumab pegol in Crohn's disease, sponsored by UCB. Primary endpoint: Long-term safety. Started Oct 2007; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2007-002716-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002716-26.